Model Number 3CX*FX15RE40C |
Device Problem
Use of Device Problem (1670)
|
Patient Problem
No Known Impact Or Consequence To Patient (2692)
|
Event Date 05/06/2019 |
Event Type
malfunction
|
Manufacturer Narrative
|
Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.(b)(4).
|
|
Event Description
|
The user facility reported to terumo cardiovascular that during pre cardiopulmonary bypass, when the device was filled and de-aired before use, but the arrival of blood from the aspirators, high resistances have been highlighted.No known impact or consequence to patient.The product was changed out.The surgery was completed successfully.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations.Upon further investigation of the reported event, the following information is new and/or changed: method code #1: 10 testing of actual/suspected device.Method code #2: 3331 analysis of production records.Results code: 213 no device problem found.Conclusions code: 67 no problem detected.The affected sample was visually inspected and did not find any obvious anomalies, in the appearance.The actual sample was rinsed, dried and build into a circuit.Bovine blood was circulated in the circuit, while the pressure drop was determined at each flow rate.The obtained values were confirmed to meet the factory's specification.The actual sample was then flushed with saline water.No clot that could lead to an increase in the pressure was found inside the sample.It is possible cause that clots may have formed inside the actual sample due to some factors and obstructed it.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on november 1, 2019.Upon further investigation of the reported event, the following information is new and/or changed: d10 (date returned to manufacturer).G4 (date received by manufacturer).G7 (indication that this is a follow-up report).H2 (follow-up due to additional information).H3 (device evaluation anticipated by manufacturer ¿ a second follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code 11.).All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Search Alerts/Recalls
|